TITLE

India on acquisition trail to push growth opportunities

AUTHOR(S)
Hui, Cheok Soh
PUB. DATE
April 2007
SOURCE
ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the move by some Indian pharmaceutical companies to tap the global outsourcing market. While generic drug makers are buying overseas assets, makers of active pharmaceutical ingredients (APIs) and formulations are eyeing the burgeoning outsourcing market for growth. India's Glenmark Pharmaceuticals bought a majority stake in Medicamenta, a Czech generic drugs firm. Ranbaxy Laboratories and Cipla have also submitted bids to buy the generic unit of Germany's Merck.
ACCESSION #
24889265

 

Related Articles

  • INDIA: Good Endings, Good Beginnings!  // Pharmaceutical Executive;Sep2011, Vol. 31 Issue 9, pS2 

    The article presents information on developments concerning the pharmaceutical industry of India. It is stated that India's 2005 change in patent regime proved to be a real paradigm shift as flagship generic companies like Cipla Ltd., Ranbaxy Laboratories Ltd., and Zydus Cadila had emerged on...

  • India on acquisition trail to push growth opportunities. Cheok Soh Hui // ICIS Chemical Business Americas;4/2/2007, Vol. 271 Issue 13, p14 

    The article reports on the acquisitions of foreign drug companies by India's pharmaceuticals companies that push growth opportunities for the country. Indian generic drug company Glenmark Pharmaceuticals has moved into the Central and East European markets through the acquisition of Medicamenta....

  • Pharmaceuticals Industry Profile: India.  // Pharmaceuticals Industry Profile: India;Dec2010, p1 

    Presents a profile of the Pharmaceuticals industry in India. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • Pharmaceuticals Industry Profile: India.  // Pharmaceuticals Industry Profile: India;Nov2008, p1 

    Presents a profile of the Pharmaceuticals industry in India. Background on Datamonitor, a business information company specializing in industry analysis; Executive summary of the industry; Market overview; Market value; Market segmentation; Competitive landscape; Leading companies in the...

  • FINANCIAL CHARACTERISTICS OF INDIAN PHARMACEUTICAL INDUSTRY: A MULTI VARIATE ANALYSIS. PRASAD, K. V. N.; AHMED, MUBASHERUDDIN; REDDY, D.MAHESHWARA // Asia Pacific Journal of Research in Business Management;Nov2011, Vol. 2 Issue 11, p1 

    Financial health of a company is a matter of concern for every stake holder of the business. It is in fact the financial position of the company that drives the decision making process of any stake holder. The present study attempts to analyze the financial performance of three major...

  • FINANCIAL HEALTH THROUGH Z SCORE ANALYSIS: A CASE STUDY ON SELECTED PHARMACEUTICAL COMPANIES. CHAKRABORTY, NIRMAL // International Journal of Research in Computer Application & Mana;Apr2014, Vol. 4 Issue 4, p29 

    Survival of the business in the modem world is possible, only when, apart from other things, it has optimum level of finance which is required to meet its both short term and long term commitment. The objective of the study is to examine the financial health of the selected four companies...

  • Ranbaxy bids for Merck generics. Liming, Keith Tan // ICIS Chemical Business Americas;3/19/2007, Vol. 271 Issue 11, p14 

    The article reports on the bid offers from various companies that want to acquire the generic business of pharmaceutical firm Merck KgaA. Merck dismissed the report that Ranbaxy Laboratories has submitted a bid worth $6 billion. Merck's Chief Financial Officer Michael Becker expects €5...

  • Ranbaxy Takes On Generics Majors. Alperowicz, Natasha // Chemical Week;7/19/2000, Vol. 162 Issue 27, p49 

    Features Ranbaxy Laboratories, a pharmaceutical company in India. Financial performance of the company in 1999; Key businesses of Ranbaxy; Historical background of the company; Manufacturing plants and units of Ranbaxy.

  • US FDA cuts drug filing fee by 8%; hikes annual facility fees by over 12%.  // FRPT- Chemical Snapshot;8/17/2014, p27 

    The article reports on the decision of the U.S. Food and Drug Administrator (FDA) to lower generation drug application fees by eight percent from October 2014 to September 2015. Topics covered include drug applications covered by the rate reduction, impact on Indian drug makers including Dr....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics